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Abstract 
Objectives: Alzheimer’s disease ȋADȌ is the most common form of dementia and 
is responsible for a huge and growing health care burden in the developed and 
developing world. The Polygenic Risk Score (PRS) approach has shown 75%-
84% prediction accuracy of identifying individuals with AD risk.  
Methods: In this study we tested the prediction accuracy of AD, MCI and amyloid 
deposition risks with PRS, including and excluding APOE genotypes in a large 
publicly available data set with extensive phenotypic data: the Alzheimer's 
Disease Neuroimaging Initiative cohort.  Among MCI individuals with amyloid 
positive status we examined PRS prediction accuracy in those who converted to 
AD.  In addition, we divided polygenic risk score by biological pathways and 
tested them independently for distinguishing between AD, MCI and amyloid 
deposition. 
Results: We found that AD and MCI are predicted by both APOE genotype and 
PRS (AUC=0.82% and 68%, respectively). Amyloid deposition is predicted by 
APOE only (AUC=79%). Further progression to AD of individuals with MCI and 
amyloid positive status is predicted by PRS over and above APOE (AUC=67%).  
In pathway-specific PRSs analyses the protein-lipid complex has the strongest 
association with AD and amyloid deposition even when genes in APOE region 
were removed (p=0.0055 and p=0.0079, respectively). 
Interpretation: The results showed different pattern of APOE contribution in 
PRS risk predictions of AD/MCI and amyloid deposition. Our study suggests that 
APOE mostly contributes to amyloid accumulation and the PRS affects risk of 
further conversion to AD.  
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Introduction Alzheimer’s disease is the most common form of dementia in the elderly people 
and is a major health problem world-wide1.  The clinical diagnosis is typically 
characterized by progressive loss of memory and cognitive function. In the last 
decade numerous relevant susceptibility loci, genes and pathways have been 
identified2–6 that have improved the understanding of this complex disease. 
However the risk for developing AD involves multiple genetic and environmental 
components, with the APOE genotype7 having the strongest genetic effect2. 
Amyloid-beta (AβȌ plays a key role in the pathogenesis of AD but little is known 
about the process of its formation in a brain. Identification of earliest pathological signature of Alzheimer’s disease requires longitudinal 
measurements of Aβ deposition in the brain by positron-emission tomography 
(PET) imaging or by measurements of Aβ reduction in cerebrospinal fluid 
(CSF). Although Aβ is necessary for the pathologic diagnosis of AD it is not 
sufficient in itself to cause cognitive dysfunction and clinical AD. It has been 
shown that amyloid deposition has low specificity for predicting development of 
AD8,9.  
The pre-clinical stage of AD starts with mild impairment in cognitive domains 
(MCI) and includes a syndrome featuring relatively isolated memory deficits10.  )n ʹͲͳͳ, the National )nstitute on Aging and Alzheimer’s Association ȋN)A-AA) created separate sets of diagnostic guidelines for the symptomatic or ǲclinicalǳ 
stages of AD11,12, where AD represents the "disease", and "dementia" represents 
the clinical syndrome. Thus a person may progress from MCI to dementia (due to 
AD); but both MCI and dementia cases may or may not be AD. 
Studying individuals that develop MCI and then further progress to AD requires 
detailed longitudinal datasets. ADNI is a multicentre study designed to assess the 
utility of various biomarkers for detecting early changes associated with MCI and 
AD. It includes collection of neuroimaging data, clinical and cognitive 
assessments, along with information on demographics and individual genetic 
profiles.  
The PRS approach aggregates the effects of multiple genetic markers identified 
through Genome-Wide Association Studies (GWAS)2 and has shown great 
potential in identifying an individual’s risk of developing AD13,14. A few studies 
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have recently used AD PRS to predict mild cognitive functions and clinical MCI15,  
however, only one has suggested that PRS could identify MCI in middle aged 
adults16 more effectively than the APOE locus alone. The PRS approach has also 
been applied to biological pathways related to AD but was not more predictive 
than APOE alone17. The implementation of the Polygenic Hazard Score (PHS) 
(which is closely related to PRS18) analysis in the ADNI data showed that PHS is 
associated to AD biomarkers (CSF and PET) in individuals without AD19, and that 
higher PHS were associated with greater rates of cognitive and clinical decline, 
even after controlling for APOE status20: however, its predictive value was not 
quantified.  
In this study we estimate the predictive accuracy of PRS differentiating a) AD 
cases versus controls, b) MCI cases versus controls, c) amyloid positive versus 
amyloid negative individuals. We also investigate whether d) the AD PRS can 
predict individuals with MCI who will progress to AD and those who will remain 
MCI, with positive amyloid deposition.  
Recently GWAS studies and exome/genome sequencing have implicated, with 
varying degrees of confidence, lipid metabolism, the innate immune system and 
endosomal vesicle recycling in late-onset AD pathogenesis21,22. Therefore we also 
examined the pathway-specific PRS association using these recently identified 
pathway6 related to AD risk.  
Methods 
ADNI: Setting/Clinical description Data used in the preparation of this article were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) is a publicly available database 
(adni.loni.usc.edu). The primary goal of ADNI has been to test whether serial 
magnetic resonance imaging (MRI), positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological assessment can be 
combined to measure the progression of MCI and early AD. The data were 
collected for about 900 individuals between ages 55-90. The initial five-year 
study (ADNI1) followed participants for 2-3 years with repeated imaging scans 
and psychometric measurements every 6 or 12 months. All ADNI participants 
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provided written informed consent. The ADNI project was extended as ADNI-GO 
and ADNI2 studies with a proportion of new and original ADNI1 participants.   
Clinical diagnosis and genetic information were available for 770 individuals 
from ADNI1, ADNI-GO and ADNI2 studies. Longitudinal data contained 
information of clinical assessments from the first visit (baseline) to the latest 
available visit with mean follow up time approximately 5 years. Details of the 
ADNI design, participant recruitment, clinical testing, and additional methods 
have been previously reported elsewhere23,24. 
Table 1 shows the classification of diagnosis and number of individuals whose 
diagnosis remained stable during the study. It also presents the diagnostic 
categories and the numbers of individuals within those diagnostic categories at 
the latest assessment, which were used for the analyses. 
To assess amyloid deposition, the latest MRI PET scans from 663 participants 
were used in the analysis (AV45 ligand threshold of 1.11). In this study we used 
the individuals’ diagnosis at the latest point of assessment.  We then tested 
whether AD polygenic risk scores are associated with AD, MCI and amyloid 
status in three main analyses a) AD vs controls, b) MCI vs controls, and c) 
amyloid positive vs amyloid negative status (Table 2). 
ADNI: genotyping and QC 
770 samples from ADNI1/GO/2 set were whole-genome sequenced (WGS) and 
genotyped using the Ilumina Omni 2.5M BeadChip (42,732,452 variants). WGS 
calls were made using the Broad Institute best practices (BWA & GATK 
HaplotypeCaller).  
Basic quality control checks were performed using standard procedure25. SNPs 
were excluded where genotype missingness was greater than 0.02, Hardy-
Wienberg equilibrium p-value was <1e-6 and SNP minor allele frequency was 
smaller than 0.01. This retained 7,808,548 SNPs for the analyses. Matching 
those SNPs with the latest publically available GWAS AD summary statistics2  
reduced that number to 5,771,686. 
Generating PRS 
Generation of PRS requires two independent datasets: summary statistics of 
association with AD in a discovery sample, and a test sample, which is 
independent of the discovery sample and contains genotypes for each 
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individual26. As the discovery sample we used summary statistics from the 
powerful study genome-wide association study (17,008 AD cases and 37,154 controlsȌ of the )nternational Genomics of Alzheimer’s Project ȋ)GAP Stage ͳȌ2. 
PRS were generated using SNPs with AD association p-value ≤Ͳ.ͷ in the IGAP 
dataset, as it has been reported as having the best prediction accuracy13. The 
SNPs were then Linkage Disequilibrium (LD) pruned (r2=0.1 and 1000kb 
window), keeping the SNPs most associated with AD. The number of SNPs after 
the LD pruning was 162,957. We included APOE εʹ and εͶ allele genotypes 
directly to the PRS with effect sizes B=-ͳ.ͲͶ and B=ͳ.ͷͷ for εʹ and εͶ, 
respectively, calculated in the ADNI data, whilst excluding the APOE region 
(chromosome 19:44,400 -19:46,500 kb)13. Prior to all analyses, the PRS were 
adjusted for the 8 principal components and then standardised.   
441 ADNI participants were part of original IGAP summary statistics2. To 
overcome a potential bias in PRS analysis due to overlapping samples, we used a 
simulation approach we previously described14. In brief, first we assessed the variation in the SNPs’ effect sizes using ͳͲͲͲ simulations when randomly 
excluding 266 cases and 173 controls (matching the numbers of overlapping 
samples). The variation in the IGAP effect sizes due to the overlap was estimated 
in terms of standard deviation (SDIGAP=0.053) from the mean (i.e. the original 
IGAP SNP beta-coefficient (BetaIGAP)). Then, new IGAP genome-wide summary 
statistics were simulated 10,000 times with adjusted effect sizes (Betaadjusted) and 
p-values for each SNP. Betaadjusted was sampled from a Normal distribution with 
mean=BetaIGAP and SD=0.053*SEIGAP,  p-valuesadjusted were redefined accordingly. 
At each simulation SNPs were re-selected and re-pruned based on LD r2=0.1 and 
1000kb window. The prediction accuracies (AUCs) reported in the Results 
section are presented as means from these 10,000 simulations. 
Genome-wide and pathway specific PRS predictions 
Initially we tested whether PRSs are associated with AD risk (AD cases vs 
controls) in the ADNI data set. Then we assessed whether the AD PRS can 
distinguish individuals with MCI from cognitively normal controls and amyloid 
positive from amyloid negative individuals. Finally, we were interested to assess 
whether PRS can predict AD risk over and above APOE in MCI individuals who 
have had positive amyloid deposition (to be precise, the MCI individuals who 
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converted to AD between the baseline and final time of assessment vs non-
converters). All analyses were performed using logistic regression models with 
the following predictors: a) APOE (εʹ + εͶȌ, b) PRS without APOE and c) full PRS 
model (a. and b. together). Gender and age we used as covariates in all analyses. 
We tested whether the PRS significantly improves the model fit over and above 
APOE alone with anova() function in R. We report the accuracy of the models in 
terms of Area Under the receiver operator Curve (AUC). In addition, we 
calculated PRS prediction accuracies (AUCs) in the extremes of PRS distribution 
for individuals whose PRS score was greater or smaller than ±1.5 standard 
deviations from the PRS mean.  
For the pathway-specific analyses we chose latest  published nine pathways 
which have been reported as playing a role in AD pathogenesis, namely: (1)- 
protein-lipid complex assembly,  (2) regulation of beta-amyloid formation, (3) 
protein-lipid complex, (4) regulation of amyloid precursor protein catabolic 
process, (5) reverse cholesterol transport, (6) protein-lipid complex subunit 
organization, (7) plasma lipoprotein particle assembly, (8) tau protein binding 
and (9) activation of immune response6. Finally, to quantify the proportion of 
variance which remains unexplained by the pathways together, we calculated 
and tested PRS for the whole genome excluding these nine pathways. 
Pathway specific PRS were generated in ADNI dataset for each individual as 
described above with and without APOE region. The PRS scores in this case were 
adjusted not only for 8 principal components but also for age and gender and 
then standardised. 
The results were considered as significant if the resulting p-value was smaller 
than or equal to 1.85x10-3=0.05/(3 scenarios × 9 pathways), corresponding to 
the Bonferroni correction for multiple comparisons. 
Results 
The prediction accuracy of AD cases (N=174) vs controls (N=224) at the last 
assessment point was AUCAPOE =76% and AUCPRS =75%, for APOE alone and for 
PRS without APOE, respectively (Table 3, first row). The best prediction accuracy 
(AUCFULL =82%) was achieved with the full model, which includes both APOE and 
PRS. An anova test (last column of Table 3) confirmed that PRS significantly 
improves the prediction accuracy of the model over and above APOE (p=1.7 x10-
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13). A similar pattern of results was observed when we compared MCI individuals 
at the last point of assessment (N=344, see Table 1 for details) with controls, 
however, the accuracy has reduced (AUCAPOE =62% , AUCFULL =68%). Again, PRS 
significantly improves the prediction accuracy of MCI risk over and above APOE 
(p=2.5 x10-11). Figure 1 shows standardised density plots of polygenic risk scores 
in AD cases (red line), controls (blue line) and MCI (orange line), where the mean 
of the PRS for the latter is between the means of the PRS for AD cases and 
controls. Interestingly, the results for prediction of amyloid deposition by PRS 
follows a different pattern: APOE alone significantly predicted amyloid 
deposition with AUCAPOE=76%, and PRS did not improve the prediction accuracy 
further.  
When we tested the full PRS model for prediction of individuals at the extremes 
of polygenic score distribution (±1.5sd from the PRS mean), the prediction 
accuracy as expected, increased (AUC=94% for AD vs controls and AUC=91% for 
MCI vs controls). 
We were interested to test whether the PRS can predict progression to AD in 
individuals with MCI. Out of 459 individuals with MCI at the baseline assessment, 
441 had known amyloid deposition status (270 were amyloid positive and 171 
were amyloid negative). The prediction accuracy of amyloid deposition in this 
subsample was AUCAPOE=79% by APOE alone and PRS did not improve the 
prediction accuracy (p=0.48, Figure 2). Out of 270 amyloid positive individuals, 
112 have progressed to AD and 150 individuals remained MCI as at the last point 
of assessment. In this case PRS did predict AD progression (AUCAPOE=63% and 
AUCFULL=69%), significantly improving the prediction over and above APOE 
(p=0.0002, Figure 2).  
Finally, we calculated pathway specific PRSs and tested them for association 
with risk for AD, MCI and amyloid deposition. The results are presented in Table 
4.  The majority of pathways were significantly associated with AD risk however 
this association was mostly driven by APOE region. Two pathways (protein-lipid 
complex, protein-lipid complex subunit) remained significant after removing 
genes in the APOE region. When we excluded all pathways from the whole 
genome PRS, we observed that a substantial part of variance still remains 
unexplained (p=2.2x10-14, last row of Table 4). Comparing amyloid positive vs 
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amyloid negative individuals, the same two protein-lipid-related pathways and 
additionally reverse cholesterol transport were significant after removing genes 
in the APOE region.  The association results of the nine pathways’ PRS with MC) 
risk were nominally significant for all pathways and the association was mostly 
attributed to APOE.  This clearly demonstrates that the pathways which contain 
APOE region are strong predictors of amyloid deposition. Protein-lipid complex 
has shown the strongest association with AD and amyloid deposition risk in all 
the analyses. The overlap of genes in the three pathways above is presented in 
Figure 3. 
Finally, we tested these pathways’ PRS for association with amyloid deposition 
in individuals with MCI and with their further progression to AD when their 
amyloid deposition status was positive. We found that protein lipid complex, 
protein-lipid complex subunit organization and reverse cholesterol transport 
pathways are also associated with amyloid deposition even after exclusion the 
APOE region (Table 5, 4th column).  
 
Discussion 
The pathological process related to AD starts long before clinical onset and lasts 
approximately 15-20 year28. It is widely believed that identifying individuals that 
have high risk of AD earlier is essential for therapeutic strategies for AD 
prevention and intervention29. Due to the diagnostic heterogeneity of MCI and 
different length of follow up assessments, the conversion rate to AD or other 
types of dementia varies widely over different studies30,31. Identifying 
individuals with MCI and monitoring them through biomarker measurements 
should provide a better understanding of the process of progression from MCI to 
AD. Although there is no generally accepted diagnostic criteria that specifies MCI 
individuals who will convert to AD it is notable that increased amyloid plaques 
that starts many years before clinical symptoms appear, plays an important role 
in brain degenerative changes. 
A reasonable prediction accuracy can be achieved with a PRS approach that uses 
genetic profile information and relates it to AD risk13,14. The PRS and its 
modifications have been assessed for association with AD and AD-related 
phenotypes in a number of studies, however the reported prediction accuracies 
Genetic risk for AD and amyloid deposition  Leonenko et al. 
 10 
have not been entirely consistent. In this study we examined prediction accuracy 
that can be achieved with APOE alone and with the full PRS model differentiating 
between AD, MCI, controls and amyloid status.  
We have shown that the best prediction accuracy can be achieved with the PRS 
which includes APOE for both AD vs controls and MCI vs controls analyses 
(AUC=82% and AUC=68%, respectively). In both analyses the PRS improves the 
prediction accuracy by about 8-9% as compared to APOE alone, which replicates 
the analyses in independent datasets published elsewhere13,14,16. Of course, GWA 
studies indicate that APOE is the strongest risk factor and other common genetic 
variants have smaller effect sizes. However, APOE region explains ~5% of SNP 
heritability whilst the whole genome explains ~24%32. In addition, PRS 
prediction accuracy shows a substantial increase in AUC which makes the PRS 
potentially clinically useful for disease risk prediction. Furthermore, AD GWAS 
risk loci have greatly expanded our understanding of the disease mechanisms. 
As expected, the accuracy of MCI prediction is lower than AD, which can be 
explained by the inclusion of a subset of MCI individuals who will not develop AD. 
For individuals with extreme PRS the AUC reaches 90% and above for both AD 
and MCI.  
The prediction of amyloid deposition showed a different pattern. In the whole 
sample the prediction accuracy with APOE alone was 76% and the PRS did not 
improve the accuracy any further (AUC remained 76%). Similar results were 
obtained when we tested the prediction accuracy of amyloid deposition in 
individuals with MCI. However, when we looked at individuals who have already 
had positive amyloid deposition and attempted to predict their progression to 
AD, the best accuracy was observed with the full PRS model which includes APOE 
region however also requires the PRS component.  
Note, that for all the used models the best prediction accuracy was achieved with 
p-value threshold of 0.5 of AD associated SNPs. The same threshold was 
previously reported in studies that were done on different genotyping 
arrays13,14. For the best prediction accuracy in clinical practice PRS should be 
generated on set of SNPs in a way that captures genetic liability of the whole 
genome. 
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The potential implication of these findings is that the APOE gene affects amyloid 
deposition but that much of the rest of the risk of disease is involved in the rate at 
which amyloid deposition causes a neurodegenerative response. Clinical trials 
have previously shown that there is little correlation between AD progression 
and accumulation of amyloid plaques supporting a hypothesis that AD 
development may have two separated stages: amyloid dependent and amyloid 
independent33. It is also known that the APOE gene influences the deposition of 
amyloid in the brain34 and that this is necessary but not sufficient for 
development of clinical AD.  Moreover it has been shown that neuronal loss and 
tangle numbers increase as AD progresses35 unlike the number of amyloid 
plaques reaches its maximum36 with the onset of clinical symptoms.  
While analysis of early onset AD firmly implicated APP metabolism and Aß 
production in the aetiology of the disease, genome wide association studies and 
exome and genome sequencing have implicated with varying degrees of 
confidence a number of potentially biologically relevant pathways in late-onset 
AD pathogenesis21,22. Of course, pathway construction is an imperfect art both 
because of the knowledge base used in the generation of the pathways and 
because proteins may have more than one function in more than one cell type.  
Nevertheless, it is valuable to divide polygenic risk by pathways both in terms of 
modeling the disease through iPSC technologies, one might like to assign high or 
low risk by pathway and, eventually, it is possible that one might wish to tailor 
therapies to pathway deficits. To dissect AD PRS by biologically relevant gene 
sets, we tested pathways enriched in AD6 identified by International Genomic Alzheimer’s Project (IGAP). All pathways, except ǲactivation of immune responseǳ 
were highly significantly associated with AD risk and amyloid deposition risk, 
however most of the signal was attributed to APOE region alone. Protein-lipid 
complex has shown the strongest association to AD and amyloid deposition risk 
in all the analyses.  
In conclusion, our results imply that APOE contributes to disease risk in a 
manner that is mechanistically different from the other genetic contributors to 
disease risk. We speculate that APOE affects amyloid deposition and that the PRS 
affects conversion from amyloid positivity to AD. Therefore, in the context of the 
amyloid cascade hypothesis, APOE acts prior to amyloid deposition and the 
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remaining genetic risk factors identified through GWAS act between amyloid 
deposition and clinical onset of Alzheimer’s disease. 
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Figure 1: Density plots of PRS for AD, MCI and cognitively normal 
participants.  
 
 
Legend: Standardised individual PRS scores for three phenotypes (AD, MCI and 
controls). 
Figure 2: Diagram of prediction of Amyloid deposition and further 
prediction of conversion of MCI individuals to Alzheimer's Diseased in 
sample that were first clinically diagnosed with MCI using APOE and AD 
PRS. 
 
Legend: PRS predictions were first made for individuals who had baseline 
diagnosis of MCI. APOE alone and full PRS model were used to predict amyloid 
deposition.  The same models were used to predict which MCI individuals 
converted to AD versus those individuals who had an MCI diagnosis using the 
latest clinical diagnosis.   
Figure 3. Overlap between three pathways. 1: protein-lipid complex (40 
genes), 2: protein-lipid complex subunit organization (35 genes), 3: 
reverse cholesterol transport (17 genes).
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Table 1: Clinical classification of diagnosis in ADNI dataset 
Diagnosis 
description 
Number of 
samples with 
diagnosis at the 
first time point 
Number of 
samples with 
diagnosis at the 
last time point 
N samples stable 
over time 
Usage for the 
analysis 
Stable control to 
control 
262 224 200 Controls 
Stable 
 MCI to MCI 
459 289 267 MCI 
Stable  
AD to AD 
47 174 46 AD 
Conversion control 
to MCI 
0 20 0 Exclude 
Conversion MCI to 
AD 
1 50 0 MCI 
Conversion MCI to 
control 
1 8 0 Exclude 
Conversion AD to 
MCI 
0 5 0 MCI 
 
Diagnosis description –classification of clinical diagnosis made for each 
participant and each time-point; 2nd column -number of participants of baseline 
diagnosis and 3rd column - numbers of participants at the last point of diagnosis. 
4th column shows number of participants who did not change their diagnosis at 
the last assessment from baseline diagnosis. Last column shows clinical 
classification of individuals based on the last available diagnosis for our analyses.  
 
Table 2. ADNI phenotypes and PET amyloid status. 
 Number of 
samples 
 N (% of  MCI) N  (% of AD) N (% of 
controls) 
Amyloid positive 357 162 (47%) 120 (69%) 65 (29%) 
Amyloid negative 304 148 (43%) 18 (10%) 128 (57%) 
NA 89 34 (10%) 36 (21%) 31 (14%) 
All samples 770 344 174 224 
Shows number of individuals with positive/negative amyloid for clinically 
diagnosed samples (MCI, AD, and controls). 
 
Table 3. PRS and APOE predictions of AD/MCI/Controls/ 
Amyloid phenotypes in ADNI. 
Model Statistical 
Characteristics 
AD vs 
Controls 
[174/224] 
MCI vs Controls 
[344/224] 
Amyloid positive vs 
Amyloid negative 
[357/304] 
APOE Beta1,3,4 [se] 0.99[0.13] 
-0.58[0.22] 
0.03[0.01] 
0.3[0.1] 
-0.5[0.17] 
-0.02[0.01] 
1.08[0.01] 
0.2[0.17] 
0.04[0.01] 
p 1.06e-18 9.6e-5 <2.2e-16 
AUC/ 
AUC* 
0.72/ 
0.76 
0.58/ 
0.62 
0.72/ 
0.76 
PRS (p<0.5) 
without 
APOE 
Beta2,3,4 [se] 0.93[0.12] 
-0.7[0.2] 
0.016[0.015] 
0.68[0.1] 
-0.47[0.18] 
-0.007[0.01] 
0.3[0.08] 
0.13[0.16] 
0.023[0.01] 
p 2.7e-18 6.e-12 1.4e-3 
AUC/ 
AUC* 
0.74/ 
0.75 
0.66/ 
0.67 
0.58/ 
0.58 
FULL PRS 
model 
Beta1-4[se] 0.93[0.13] 
0.88[0.13] 
-0.63[0.24] 
0.04[0.02 
0.26[0.1] 
0.66[0.1] 
-0.47[0.18] 
-0.002[0.01] 
1.06[0.1] 
0.22[0.09] 
0.22[0.17] 
0.05[0.01] 
p 1.9e-30 1.1e-12 2.3e-29 
AUC/ 
AUC* 
0.81/ 
0.82 
0.67/ 
0.68 
0.75/ 
0.76 
Anova p (PRS above APOE) 1.7e-13 1.8e-10 0.038 
Beta1=beta (e2+e4), Beta2=beta(PRS), Beta3=beta(sex), Beta4=beta(age); 
AUC-area under the curve without taking gender and age into account; 
AUC*- area under the curve where gender and age were used as predictors; 
 
Legend: 1st column –three scenarios where PRS predictions were made: APOE 
alone, PRS without APOE and full model (APOE plus PRS (p<0.5)); 2nd column- 
statistical characteristics that were calculated for each model, these includes 
effect size (beta) with standard error (se), p-values and AUC (with and without 
gender and age) and p-value of significance PRS above APOE model; columns 3-5 
represent three analyses with number of samples where different models were 
tested. 
Table 4: Prediction of AD and amyloid deposition risk with pathway-
specific PRSs  
Pathways 
Number 
of 
Genes 
AD (174) vs Controls (224) 
Amyloid positive (357) vs 
negative (304) 
Beta p-value 
p-value 
(no 
APOE 
region) 
Beta p-value 
p-value 
(no 
APOE 
region) 
protein-lipid complex 
assembly 
20 0.87 3e-13 0.35 0.94 4e-21 0.4 
regulation of beta-
amyloid formation 
10 0.79 1.1e-11 0.09 0.81 8.9e-17 0.47 
protein-lipid 
complex 
40 0.91 8.14e-14 5.5e-3 0.96 1.8e-21 7.9e-3 
regulation of amyloid 
precursor protein 
catabolic process 
12 0.79 1.1e-11 0.09 0.81 9.6e-17 0.49 
tau protein binding 11 0.77 3.1e-11 0.39 0.82 4.8e-17 0.6 
reverse cholesterol 
transport 
17 0.84 2.4e-12 0.07 0.93 2.1e-19 0.03 
protein-lipid 
complex subunit 
organization 
35 0.92 8.e-14 0.03 0.97 9.67e-22 0.03 
plasma lipoprotein 
particle assembly 
18 0.89 2e-13 0.66 0.94 3.6e-21 0.98 
activation of immune 
response 
432 0.18 0.06 0.06 0.21 6.8e-3 0.01 
Whole genome 
without all pathways 
- 0.93 2.2e-14 - 0.38 9.1e-6 - 
Legend: 1st column-name of pathways that were analysed, 2nd column- number of genes in each 
pathway, PRS pathways-specific effect sizes with p-values and p-values (no APOE region) of the 
models are presented in columns 3- 8 for AD vs controls and amyloid deposition status.
 
 Table 5: Prediction of amyloid deposition in individuals with 
MCI and of progression to AD in individuals with MCI and 
positive amyloid deposition with pathway-specific PRSs 
 
 
Legend: 1st column-name of pathways that were analysed, PRS pathways-specific 
effect sizes with p-values and p-values (no APOE region) of the models are 
presented in columns 2- 7. 
Pathways 
Amyloid positive (270) vs amyloid 
negative (171) 
MCI and amyloid positive  
(AD (112) vs MCI (150)) 
Beta P 
P  
(no APOE 
region) 
Beta P 
P  
(no APOE 
region) 
protein-lipid 
complex assembly 
1.11 1.92e-17 0.2 0.48 2.7e-4 0.81 
regulation of beta-
amyloid formation 
0.95 7.6e-14 0.2 0.30 9e-3 0.11 
protein-lipid 
complex 
1.12 1.1e-17 3.1e-3 0.51 1.5e-4 0.23 
regulation of 
amyloid precursor 
protein catabolic 
process 
0.95 8.4e-14 0.2 0.3 9.4e-3 0.12 
tau protein binding 0.99 2.2e-14 0.2 0.2 0.08 0.24 
reverse 
cholesterol 
transport 
1.05 1.9e-15 0.03 0.31 0.01 0.24 
protein-lipid 
complex subunit 
organization 
1.1 1.2e-17 0.05 0.51 1.9e-4 0.64 
plasma lipoprotein 
particle assembly 
1.09 3.4e-17 0.9 0.51 1e-4 0.31 
activation of 
immune response 
0.18 0.068 0.09 0.08 0.54 0.76 
Whole genome PRS 
without pathways 
0.36 2.1e-3 - 0.6 8.8e-5 - 



